Synthesis and development of VR1 antagonists

ORGN 739

Anthony O King, kinga@amgen.com, Robert D. Larsen, Oliver Thiel, Jason Tedrow, Anil Guram, Charles Bernard, Yuelie Liu, T J Xiang, Tracy Bostick, Mina Dilmeghani-Seran, Thomas Storz, Richard Crockett, Liang Huang, Xin Wang, Emilio Bunel, Margaret Faul, Mike Martinelli, and Paul Reider. Chemical Process R&D B29-2-A, Amgen, Inc, One Amgen Center Drive, Thousand Oaks, CA 91320
The synthesis and development of the VR1 clinical candidates AMG 517 and AMG 628 will be described. Both approaches benefited from the development of a highly selective etherification step of 4,6-dichloropyrimidine with the 4-hydroxy-2-acetamidobenzothiazole. Subsequent Suzuki coupling or amination, respectively, afforded the drug candidates. Practical preparations of the benzothiazole and the piperazine will also be presented

 

Combinatorial, Parallel and Process Chemistry, Heterocycles, Aromatics, New Reactions and Methodology
8:00 PM-10:00 PM, Wednesday, August 22, 2007 BCEC -- Exhibit Hall - B2, Poster

Division of Organic Chemistry

The 234th ACS National Meeting, Boston, MA, August 19-23, 2007